Vineet Laboratories Ltd.

As of March 31, 2026, Vineet Laboratories Ltd. carries a market capitalization of 558.13M, placing it among publicly traded companies globally. Its enterprise value stands at 840.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Vineet Laboratories Ltd. has 19.21M shares outstanding.

As of March 31, 2026, Vineet Laboratories Ltd. trades at a trailing price-to-earnings ratio of 31.51. The price-to-sales ratio is 0.59, and the price-to-book ratio stands at 1.22.

As of March 31, 2026, Vineet Laboratories Ltd. trades at an EV/EBITDA multiple of 9.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.86 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 840.64M versus a market cap of 558.13M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Vineet Laboratories Ltd. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 99.39, indicating elevated leverage, while an interest coverage ratio of 1.74 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Vineet Laboratories Ltd. posted a return on equity (ROE) of 3.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.15 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.34, useful for judging operating efficiency across full business cycles. The company generates approximately 10.42M in revenue per employee across its workforce of 57.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.68 indicates how many times Vineet Laboratories Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Vineet Laboratories Ltd. recorded 1.72M in income tax expense. That works out to an effective tax rate of 13.39, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.83M, leaving 11.11M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Vineet Laboratories Ltd.'s stock has gained approximately 3.69% over the past 52 weeks. The 50-day moving average sits at 37.20, while the 200-day moving average is 34.81.

Over the twelve months ended March 31, 2026, Vineet Laboratories Ltd. generated 594.01M in revenue and converted that into 11.11M in net income, yielding earnings per share of 0.92. EBITDA reached 84.79M, while operating income came in at 60.64M.

As of March 31, 2026, Vineet Laboratories Ltd. holds 170.75M in cash and equivalents against 453.25M in total debt, resulting in a net debt position of 286.30M. Total book value stands at 456.02M, with working capital of 315.44M providing operational flexibility.

Over the twelve months ended March 31, 2026, Vineet Laboratories Ltd. posted a gross margin of 35.00, reflecting its pricing power and cost economics. The operating margin of 10.21 and net profit margin of 1.87 provide insight into operational efficiency.

Vineet Laboratories Ltd.'s most recent stock split took place on December 23, 2025 with a 100:119 split ratio.